Amal Therapeutics SA

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSORetiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handoverChristopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basis Lausanne, Switzerland, December 1, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief Scientific Officer and the promotion of Interim Chief Financial Officer Christopher Roberts to Chief Financial Officer. Dr. Derouazi succeeds the former CSO, Dr. Marie Kosco-Vilbois, who is retiring and will remain with AC Immune as an expert consultant in immunology to ensure continuity and a smooth transition. Dr. Madiha Derouazi, an accomplished immunologist, joins from Speransa Therapeutics where she had been CEO since inception in 2021, leading development of a novel platform of prophylactic vaccines. Previously, she founded AMAL Therapeutics in 2012, an immuno-oncology company developing a new generation of therapeutic cancer vaccines, and served as CEO and CSO of the company until 2022. Dr. Derouazi led AMAL’s acquisition by Boehringer Ingelheim for EUR 425 million in 2019. She holds a PhD in Cellular Biotechnology from the Swiss Federal Institute of Technology (EPFL) in Lausanne which was followed by postdoctoral work concentrating on tumor immunology and vaccine development. Christopher Roberts joined AC Immune in 2019 and has served as Vice President, Finance and Interim CFO of AC Immune since 2022. He has extensive experience of SEC reporting, initial and follow-on public offerings and financial controls. He is a UK Chartered Accountant and holds a Bachelor of Science in Accounting, Auditing and Finance from Lancaster University. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “I am delighted to welcome Madiha Derouazi as our new CSO and to confirm Chris as CFO. Madiha has an outstanding international track record as an immunologist, entrepreneur, and vaccine developer. Her expertise in vaccines will be invaluable to AC Immune as we continue to transform our company into a global leader in precision medicine to diagnose, treat and prevent neurodegenerative diseases with active immunotherapies and other therapeutic modalities.” “I would like to take this opportunity to warmly thank Marie for her dedicated service to AC Immune. Her experience has proven instrumental for optimizing our SupraAntigen vaccine technology platform as we have expanded and developed our broad pipeline. We wish her all the best for the future.” About AC Immune SA AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments. SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU. The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release. For further information, please contact: Head of Investor Relations & Corporate CommunicationsGary Waanders, Ph.D., MBAAC ImmunePhone: +41 21 345 91 91Email: gary.waanders@acimmune.comU.S. InvestorsCorey Davis, Ph.D.LifeSci AdvisorsPhone: +1 212 915 2577 Email: cdavis@lifesciadvisors.comInternational MediaChris MaggosCohesion BureauPhone: +41 79 367 6254Email: chris.maggos@cohesionbureau.com Forward looking statementsThis press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement. Attachments 20231201_ACIU_Management change-FINAL AC Immune appoints Madiha Derouazi as CSO AC Immune appoints Christopher Roberts as CFO

None  Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.  Ayala sheds execs amid Advaxis merger  Advaxis, Ayala Pharmaceuticals  A new merger deal has Advaxis and Ayala joining forces, though not everyone from Ayala’s team will be coming with. Advaxis CEO Kenneth Berlin will guide the newly created company—which has yet to decide on a name—while Ayala CEO Roni Mamluk, Ph.D., will resign. That’s not the only Ayala loss, with CFO Yossi Maimon and CMO Gary Gordon, M.D., stepping down, though Gordon will remain in an advisory role “for a period of time.” The new company’s board will include two members designated by Advaxis and four chosen by Ayala alongside Berlin.  Each biotech will continue to propel its lead program, with the new company aiming to prioritize the development of AL102 to treat desmoid tumors and ADXS-504 for patients with prostate cancer. With only $20 million on hand, Ayala was facing a potential cash crunch. But Advaxis may have solved its problems—in return for the hope of a return to the Nasdaq after dropping from the leading stock exchange down to the OTC Markets in 2021. Fierce Biotech Scynexis CEO to retire amid strategic restructure, C-suite shake up Scynexis Scynexis is shedding C-suite execs as part of strategic restructuring that includes layoffs and slimming down its pipeline.  President and CEO Marco Taglietti, M.D., will retire after more than seven years leading the company, effective Dec. 31. He will also step down from the board of directors. Chief Medical Officer David Angulo, M.D., will take Taglietti’s spot after serving as CMO for the last seven years.   As part of the corporate restructure, Scynexis’ chief commercial officer position is being eliminated, meaning Christine Coyne, who has served in this leadership role for more than a year, will leave the company.  Meanwhile, former Athersys CFO Ivor Macleod will join as Scynexis’ chief financial officer starting Oct. 24. Release New face of Mirror Biologics: Former Luzsana leader Scott Filosi tapped as CEO   Mirror Biologics Mirror Biologics has tapped seasoned exec Scott Filosi to be the new face of the company as it gears up to become a commercial business.   Starting Nov. 15, Filosi will take the reins from interim CEO and founder Dr. Michael Har-Noy, who took up the temporary post after former interim CEO Adi Raviv departed in February.   In his new role, Filosi will oversee Mirror as it looks to commercialize its lead product, dubbed AlloStim, an "off-the-shelf," non-genetically manipulated, disease agnostic immunotherapy.  Filosi has years of market access and drug launch experience across multiple therapeutic areas, serving in numerous senior leadership roles at Merck KGaA, UCB Pharma, Boehringer Ingelheim and Johnson & Johnson.  Most recently, Filosi was founding CEO of Luzsana Biotechnology, a spinout from Jiangsu Hengrui Pharmaceutical, one of Asia’s largest pharmas. There, Filosi led the development of several oncology programs and aimed to “quantifiably reduce costs” of medicines.  Mirror’s mission runs certain parallels with Luzsana’s, driven by the goal to provide patients with non-toxic, affordable and widely accessible immunotherapies. Release > Former Biogen finance leader John Applegate is joining Verge Genomics as chief financial officer. After more than 14 years at Biogen, Applegate was most recently at Valo Health. Release > AstraZeneca’s rare disease business arm Alexion has appointed Scott Weintraub to serve as SVP and head of U.S. commercial operations, a company spokesperson told Fierce Biotech via email. Weintraub first joined Alexion in 2019, most recently serving as the company’s VP and head of global commercial strategy. > Lyn Baranowski is taking on her first chief executive role, joining pulmonary disease-focused Avalyn Pharma. Prior to this, she was chief operating officer at Altavant Sciences. Release > Bristol Myers Squibb alum Robert Petit has been tapped to lead early clinical development at Orionis Biosciences. Since leaving BMS in 2010, Petit has held a number of roles in biotech, including chief scientific officer at Advaxis. Release  > Flagship-founded Alltrna is appointing Caroline Kӧhrer, Ph.D., as VP of discovery platform. She won’t be moving far, bouncing over from Moderna, another Flagship company, where she was director of RNA science. Release > Some three months after temporarily taking the role of chief medical officer, Fulcrum Therapeutics R&D lead Judith Dunn, Ph.D., is resigning. But she’s not bolting out of the door, staying on in a consulting role until January 3, 2023. Disclosure > Senda Biosciences has a couple of new additions to its leadership team, naming Lori Rudolph-Owen, Ph.D., as chief operating officer and Barbara Bispham as SVP and general counsel. The company is two months removed from closing a $123 million financing round. Release > Ashvattha Therapeutics has tapped Steve Maricich, M.D., Ph.D., to serve as chief medical officer as the biotech prepares to launch clinical trials next year. Maricich joins Ashvattha from Calibr and Scripps BioVentures, where he also served as chief medical officer. Release > Cancer immunotherapy company Abalos Therapeutics has chosen Thomas Bogenrieder, M.D., P.h.D., to take up the role as chief medical officer. Bogenrieder previously served as chief clinical officer for Amal Therapeutics and has held leadership roles at Evaxion Biotech, Boehringer Ingelheim and GSK. Release > David Hollander, M.D., is joining Revance Therapeutics as chief medical officer. Hollander joins the commercial-stage biotech from Aerie Pharmaceuticals, where he served as head of R&D. Release > Belgium biotech Bioxodes has appointed a new CEO as the company prepares to launch a phase 2a trial for patients with intracerebral hemorrhage. Marc Dechamps will take over the role from company founder Edmond Godfroid, who will assume the role of chief operating officer alongside his existing responsibilities as chief scientific officer. Dechamps is a biologist with more than 30 years of experience, including working at GSK and ViiV Healthcare. Release > Ankyra Therapeutics has tapped Joseph Elassal, M.D., to fill its chief medical officer position after former CMO Howard Kaufman, M.D., transitioned to helm the biotech as president and CEO. Previously, Elassal has held roles at Regeneron, Pfizer and PhRMA, among others. Release 

→ Revance feels like it has a competitive advantage over AbbVie ’s blockbuster Botox with only biannual injections of its freshly approved Daxxify , as opposed to the injections every three or four months that Botox requires. But you come at the king, you best not miss, and as Daxxify hits the market, Revance has now tapped David Hollander as CMO. Hollander was previously the chief R&D officer at Aerie Pharmaceuticals , which was sold to Alcon a couple months ago in a $770 million deal , and he has familiarity with the Botox developer through his 10 years at Allergan . From 2011-16, he was Allergan’s VP, global therapeutic area head in clinical development for anterior segment and consumer eye care. The Nashville biotech is also testing DaxibotulinumtoxinA in patients with cervical dystonia, among other conditions. → Now under the leadership of ex- Intercept CEO Mark Pruzanski and part of this year’s Endpoints 11 class , obesity startup Versanis Bio has welcomed Kenneth Attie as CMO and Aditya Venugopal as SVP, corporate development and strategic planning. Attie was one of the staffers left out in the cold at Imara as it whittled down to a six-person company in April but turned around its fortunes by reverse merging with Enliven Therapeutics last week. Before he was Imara’s medical chief, Attie spent 11 years at Acceleron as VP, medical research. In a mini-reunion, Venugopal worked for Pruzanski at Intercept as head of strategic planning, and since 2020 he had been VP of business development for Luca Santarelli at VectivBio . → Wholesale changes are being made at Scynexis , and not just with a slimmed-down pipeline as it shops around for a commercialization partner with Brexafemme . CEO Marco Taglietti will retire on Dec. 31, setting up CMO David Angulo to replace him as we ring in 2023. Ex- Eisai and Athersys finance chief Ivor Macleod ’s first day as CFO will be Oct. 24, while chief commercial officer Christine Coyne ’s job has been phased out. Scynexis will also be making more cuts to a staff that stood at 56 employees as of March 1, but the exact number wasn’t revealed. Kyle LaHucik has more on a company in flux . → Lyn Baranowski has taken over for Bruce Montgomery as CEO of Seattle-based pulmonary disease outfit Avalyn Pharma , once known as Genoa Pharmaceuticals . Since 2018, Baranowski knows the pulmonary space well from her four years as operations chief at Altavant , and from 2013-18, the Novartis alum was SVP of corporate development & strategy with Melinta Therapeutics . Avalyn’s lead program is an inhaled version of pirfenidone named AP01 for idiopathic pulmonary fibrosis. → The CEO situation has taken a turn at Maravai LifeSciences , where former Danaher SVP Trey Martin had succeeded Carl Hull earlier this month — or so we thought. Three Danaher subsidiaries have a bone to pick with the appointment, suing Martin and Maravai , and “alleging that Martin is in breach of a noncompetition agreement.” With a temporary restraining order in place, Hull didn’t hide his displeasure as he retakes his old position. “We have complete confidence in Trey and are appalled that Danaher would seek to leverage a noncompetition agreement to prevent Trey from advancing his career,” Hull said in a statement. → Alice Zhang ’s AI drug discovery shop Verge Genomics has installed 14-year Biogen vet John Applegate as CFO. Formerly the VP of finance & accounting with Valo Health , Applegate closed out his Biogen career in 2019 as head of R&D finance. Zhang just contributed to Ochre Bio ’s $30 million Series A , while Verge’s latest round of funding totaled $98 million in December 2021 . In another Biogen connection, ex-R&D chief and current Voyager CEO Al Sandrock joined the board of directors at Verge in February. → Zentalis Pharmaceuticals has been relentless with its leadership moves since the Kim Blackwell era began in May with a $200 million cash infusion , promoting co-founders Cam Gallagher and Kevin Bunker while picking up a CMO and general counsel in that span. This week Zentalis returns to Peer Review with Mark Lackner as chief translational officer, head of biomarker strategy. Before he was head of biology and translational sciences for Ideaya Biosciences , Lackner led the oncology early-stage biomarker group as part of his 13 years at Genentech . → Co-founded and chaired by Tillman Gerngross , oncology outfit Ankyra Therapeutics has recruited Joseph Elassal as CMO. Elassal has two stints at Regeneron on his résumé: one from 2012-18, and the other as senior medical director, global medical affairs, oncology since 2020. In between, he was a deputy VP at PhRMA and a senior medical director for Replimune . Ankyra bagged a $45 million Series B in November 2021 with the help of Polaris , GV and a number of other investors. → Another Gerngross company, Invivyd , came out swinging when it was known as Adagio , with big aspirations for its Covid-19 monoclonal antibody along with bigger bucks. But the drug struck out against Omicron , and Gerngross was gone as CEO within a couple months. The name changed to Invivyd a few weeks ago, but the unease remains the same, as CFO/CBO Jane Henderson and chief commercial officer Eric Kimble have packed their bags. Fred Driscoll , a CFO with Renovacor , Flexion Therapeutics and Novavax , will bridge the gap as interim finance chief as Invivyd also says goodbye to an unspecified number of staffers. → Pittsburgh’s NeuBase Therapeutics has also been beset by layoffs, dismissing 60% of its employees this week while pivoting to gene editing. Sandra Rojas-Caro , NeuBase’s CMO since May 2021 who also began another role as head of R&D this past April, handed in her resignation. → As George Church ’s Colossal Biosciences continues its quest to bring back the woolly mammoth, its computational biology spinout Form Bio has locked in Mark Swendsen as chief revenue officer. Swendsen held the same position at DNAnexus before coming to Form Bio, which christened the boat with a $30 million Series A round in late September. → Flagship ’s Alltrna has dipped into the talent pool of the incubator’s most famous creation to find its VP, discovery platform. Caroline Köhrer comes to the tRNA player after more than two years as Moderna ’s director of RNA science — a key cog in the development of its Covid-19 vaccine — and five years overall. Alltrna chief Michelle Werner was part of Flagship’s rapid-fire CEO-partner appointments in April that included Margo Georgiadis and former AbbVie president Michael Severino . → While we have Flagship companies on our mind, Senda Biosciences has pulled in two new execs with the appointments of Lori Rudolph-Owen as COO and Barbara Bispham as general counsel. Rudolph-Owen hails from Goldfinch Bio , where she most recently served as chief development officer. Prior to that, Rudolph-Owen held a number of roles at Pfizer , AMAG Pharmaceuticals , MGI Pharma , Vertex and Millennium Pharmaceuticals . Bispham joins Senda from BridgeBio , where she was VP, head of legal. Prior to that, Bispham was with Goodwin Procter , Cooley and Reed Smith . → Not to be confused with the great basketball Hall of Famer Bob Pettit , Robert Petit has become the head of early clinical development at Orionis Biosciences , a cancer biotech that racked up $55 million in financing this week. Petit chairs the scientific advisory board and is the ex-CSO of Advaxis , which happened to make news the same day as Orionis’ raise by merging with Ayala Pharmaceuticals . One more thing about Orionis: Cormorant Asset Management founder and chief executive Bihua Chen is now a member of the board. → Nigel Horscroft has settled in as CSO of German antiviral biotech Atriva Therapeutics , replacing current scientific advisory board chairman Oliver Planz . Horscroft brings Big Pharma credentials with him from Pfizer, and during his time at CureVac from 2012-20, he was promoted to area head, molecular therapy. Atriva has also picked up two other clinical execs this year: Stephan Witte (VP, clinical science and operations) in January and Tim Overend (VP, clinical development and regulatory) in July. → Staying in Germany, Boehringer Ingelheim and GSK alum Thomas Bogenrieder has joined adenovirus-based cancer biotech Abalos Therapeutics as CMO. Bogenrieder had held the role of chief clinical officer at Swiss-based AMAL Therapeutics since July 2020 and is the ex-medical chief of Evaxion Biotech . A year ago around this time, Abalos topped off its Series A with $37.6 million in additional funding . → In September 2021, we told you about Roche vet Anja Harmeier taking the CEO job at Belgian remyelination biotech Rewind Therapeutics . Fast forward to this week, where Rewind has selected Irene Knuesel as CSO. Knuesel has Roche ties herself, closing out her six-year tenure in 2019 as the pharma giant’s head of the neuroimmunology and neurodegeneration section. Incidentally, Roche is under the microscope again in the Alzheimer’s space as we await data for its resuscitated drug gantenerumab . → Targeting solid tumors, Immuneering — one of many biotechs that took the Nasdaq plunge at the zenith of IPOs in 2021 — has brought in Leah Neufeld as chief people officer. Neufeld has worked in human resources for companies of all sizes, with J&J , Daiichi Sankyo and Prevail packing her résumé. The one-time head of HR at Intercept was recently the chief human resources officer for Jiangsu Hengrui subsidiary Luzsana Biotechnology . → Ashvattha Therapeutics , a hydroxyl dendrimer (HD) biotech based in the Bay Area, has pegged Steve Maricich as CMO. Maricich recently held the CMO post at Scripps ’ Calibr , and he’s been the medical chief at Allievex , the developer of a drug for Sanfilippo syndrome type B that was once in BioMarin ’s hands. → Jessica Atkinson has been appointed CBO of ImmuneID , a biotech out of Stephen Elledge ’s lab at Harvard that’s zeroing in on antibodies with its AI platform, called aiSPIRE. Atkinson rose to VP, business development at Foundation Medicine in 2019 after Roche’s $2.4 billion takeover , and she just had a brief run as SVP, business development of Glympse Bio . → Plainly-named IO Biotech , a Nasdaq newcomer in 2021 that’s going after IDO and PD-L1 with its cancer drugs IO102 and IO103 , has enlisted Amy Sullivan as CFO. Sullivan had a seat at the negotiating table as chief strategy officer of Kiadis when it was purchased by Sanofi for $358 million. The ex-SVP of corporate affairs at Keryx Biopharmaceuticals was also VP, investor relations and corporate communications with AMAG Pharmaceuticals. → Belgian biotech Bioxodes is changing up the top exec seat with the appointment of Marc Dechamps as CEO. Dechamps takes over the reins from company founder Edmond Godfroid , who is transitioning into the roles of COO and CSO. Dechamps brings with him experience from his times at GSK and ViiV Healthcare to the new role. → San Diego RNA editing biotech ADARx Pharmaceuticals is a busy bee in Peer Review too, naming Feriandas Greblikas as VP of clinical development after hiring CFO Chris Prentiss and CMC VP Christopher Claeboe this year. A veteran of Novo Nordisk , Biogen and Baxter , Greblikas comes to ADARx from Travere Therapeutics , where he was a senior medical director and clinical development lead. And in a previous gig, he worked for JJ Bienaimé as BioMarin’s medical director of phenylketonuria clinical trials. → Coming up on a year since its $60 million Series A , STAT3- and STAT6-focused Recludix Pharma is back in Peer Review with Paul Smith as SVP of biology. Smith, the ex-global research lead for Gilenya with Novartis, has also been senior director of inflammation and autoimmunity at Incyte . He held the role of VP, discovery biology at Connect Biopharma before pivoting to Recludix, a company out of San Diego that introduced CBO Matthew Caldemeyer in late September. → Transpacific oncology biotech AnHeart Therapeutics , which secured a $61 million Series B round last year, has welcomed aboard Heinrich Farin as senior medical director, clinical research and Michael Humphries as VP, head of US medical affairs. Farin hails from Mirati , where he served as senior medical director and has a prior stint as global senior medical director, clinical research and development at BeiGene . Earlier in his career, Farin had roles at Ariad Pharmaceuticals and Baxalta . Meanwhile, Humphries brings expertise from his time at Takeda Oncology , where he served as senior scientific director of global medical affairs. Prior to Takeda , Humphries had gigs at Bayer Healthcare Pharmaceuticals and Array Biopharma . → Swiss LILRB (leukocyte immunoglobulin-like receptor subfamily B) biotech ImmunOs Therapeutics has pegged Hilmar Ebersbach as VP, antibody development and protein engineering. Ebersbach had spent the last 15 years in biotherapeutic engineering and gene therapy at the Novartis Institutes for BioMedical Research . → Believe it or not, Daniel Ripley has ventured off to HighTide Therapeutics as SVP, business development. Ripley is an Ionis BD vet who led global business development for the last two years at Alpha Biopharma , and as the brave souls of HighTide give NASH a whirl with its lead program HTD1801 , he also has experience in the space as SVP of business development, program and alliance management at Conatus Pharmaceuticals , a Novartis partner plagued by NASH failures that merged with Histogen in 2020. → GSK India has named Bhushan Akshikar as managing director, succeeding Sridhar Venkatesh , who is transitioning to a senior role within the GSK Group. Akshikar joined GSK India in September 2011. Prior to GSK, Akshikar had a 15-year stint at J&J’s Janssen . → Ex-AMAG Pharmaceuticals CEO Brian Pereira has been named chairman at KalVista following the resignation of Martin Edwards and a resounding trial failure. Earlier this month, KalVista had to stop a Phase II trial of its hereditary angioedema drug KVD824 after issues with liver enzymes were detected throughout all three treatment groups. Pereira has been president and CEO of Otsuka sub Visterra since 2013. → Proteomics biotech SomaLogic , which reverse-merged onto Nasdaq with Eli Casdin’s SPAC with a $1.2 billion valuation last April, has tapped Troy Cox as executive chair of the board of directors, taking over from Chuck Lillis , who will remain on the board. Cox formerly served as president and CEO of Foundation Medicine and was SVP and officer at Genentech and held roles at UCB , Sanofi-Aventis and Schering-Plough . → Rocket Pharmaceuticals chief Gaurav Shah is now chairman of the board at Swiss gene therapy developer Anjarium Biosciences , which unveiled a $61 million launch round in September 2021 thanks to such big-name investors as Pfizer and Abingworth . And after joining the board at Oncorus in June, ex- Dicerna CEO Doug Fambrough also has a place in Anjarium’s boardroom. → Cell processing shop Curate Biosciences has reserved space for Shah’s chief technical officer at Rocket, Mayo Pujols , on the board of directors. Pujols was in charge of global manufacturing for liso-cel (now Breyanzi ) as Celgene ’s VP of global CAR-T operations and technology. → Belgian infectious disease biotech ExeVir has appointed Jeanne Bolger to chair the board of directors. After 13 years at GSK, Bolger switched to another pharma giant as VP of scientific licensing at J&J, later becoming the VP of venture investing at Johnson & Johnson Innovation (JJDC) . → Theseus Pharmaceuticals — a TKI player from OrbiMed whose stock $THRX recently hit its nadir practically a year to the day that it joined Nasdaq in a none-too-shocking development in this market — has added Incyte CMO Steven Stein to the board of directors. Stein is a former clinical development exec with GSK and Novartis Oncology . → Geron ’s EVP, corporate strategy and chief commercial officer Anil Kapur is making his way to the board of directors at Verastem Oncology . Kapur is the former head of early assets, biomarkers and external innovation for worldwide oncology commercialization for Bristol Myers Squibb and the ex-CCO at Actinium . → China-based Hangzhou Qihan Biotech has brought on Tony Ho to its board of directors. Ho joins after a four-year stint at CRISPR Therapeutics , where he most recently served as EVP and head of research & development. Ho’s prior experience includes roles as SVP and head of oncology integration and innovation at AstraZeneca , head of neurology and ophthalmology at Merck and co-founder and CSO at Neuronyx . → Following a recent Series C financing round, Inversago Pharma has reeled in Ed Mathers and Nanna Lüneborg to its board of directors. Mathers is a general partner at New Enterprise Associates and has previously served as EVP, corporate development and venture at MedImmune . Mathers currently serves as a director to a host of companies, including Rhythm Pharmaceuticals , Synlogic , Senti Bio , Inozyme , Akouos and Affinia . Meanwhile, Lüneborg is a general partner at Forbion and formerly served a decade-long stint as a partner at Novo Ventures . → The Illinois Biotechnology Innovation Organization ( iBIO ) has added three new faces to its board of directors with the appointments of: Rahul Jerath (senior director, head of oncology business development & acquisitions at AbbVie), Phil Tennant (SVP and head of oncology business unit at Astellas ), and Joe Whalen (SVP, alliances & international business development at Horizon Therapeutics ). Illustration: Kim Ryu for Endpoints News